(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
In this book the pathophysiology, diagnosis, and therapy of most aspects of peptic ulcer disease are examined in detail. Covered are the pharmacology of the parietal cell and the latest hypotheses for the development of acid-peptic disease including epidermal growth factor, gastrin and other peptide hormones, fatty acids and prostaglandins, helicobacter pylori, and gastric acid hypersecretion including Zollinger-Ellison syndrome. The book also deals with the newer antisecretory medication such as omeprazole with a review of H2-receptor antagonists. Rounding off the subject are chapters on gastroesophageal reflux disease, upper GI endoscopy, and videoendoscopy including digital imaging. This volume addresses a wide range of physicians who are interested in all aspects of acid-peptic disease. What distinguishes this volume from others is the timely update on a number of important issues pertaining to acid-peptic disease. Not only does it review a number of topics that are of great interest at the present time, but it introduces a vast amount of new unpublished data.
Contents:
1 Pharmacology of the Parietal Cell.- A. Introduction.- B. Anatomy of Gastric Mucosa.- C. Secretion by the Stomach.- I. General.- II. Secretion and Absorption by Surface Epithelial Cells.- D. Gastric Barrier.- E. Agents Thought to Affect Gastric Barrier function.- I. Sucralfate.- II. Prostaglandins.- III. Bismuth Compounds.- F. Ion Transport by the Parietal Cell.- I. Apical Surface.- II. Basal Lateral Surface.- III. Stimulation of Acid Secretion.- IV. Mechanism of Parietal Cell Stimulation.- G. Receptor Antagonists.- I. Muscarinic Antagonists.- II. H2 Antagonists.- H. Mechanism of Gastric Proton Pump.- I. Transport by ATPase.- II. Reaction Cycle.- III. Structure of Gastric H+, K+-ATPase.- J. Inhibitors of H+, K+-ATPase.- I. Omeprazole.- 1. Effects on Acid Secretion.- 2. Duration of Action.- 3. Mechanism of Action.- II Reversible H+, K+-ATPase Inhibitors.- III. Clinical Use of Pump Inhibitors.- References.- 2 Epidermal Growth Factor.- A. Introduction.- B. Perspective on Growth Factors.- C. Perspective on Mucosal Disease.- D. EGF Structure.- E. Structure-Activity Relationships.- F. Biological Effects.- G. Gastrointestinal Activity.- I. Developmental Effects of EGF.- II. Gastric Acid Secretion.- III. Trophic Effects.- H. Conclusion.- References.- 3 Gastrin and Other Peptide Hormones.- A. Introduction.- B. The Molecular Heterogeneity of Gastrin.- C. Gastrin Release.- D. Autonomic Control of Gastrin Release.- E. Bombesin-Like Peptides.- F. Somatostatin.- G. Mechanism of Gastrin-Induced Gastric Acid Secretion.- H. Gastrin and Peptic Ulcer Disease.- J. Hypergastrinemic Syndromes.- K. Conclusion.- References.- 4 The Role of Essential Fatty Acids in Gastric and Duodenal Protection and Ulcer Therapy.- A. Cytoprotection and Prostaglandins.- I. Definition of Cytoprotection.- II. Mucosal Sites of Cytoprotection.- 1. Protection of the Mucosal Microvasculature.- 2. Direct Protection of Gastric Mucosal Cells.- III. Metabolism of Natural and Synthetic Prostaglandins.- B. Arachidonic Acid Cascade and Prostaglandin Synthesis by Gastric and Duodenal Mucosa.- I. Arachidonic Acid Cascade.- II. Sources of Arachidonic Acid from Mucosal Pools.- III. Control of Mucosal Prostaglandin Synthesis.- C. Dietary Sources of Arachidonic and Linoleic Acids.- I. Food Sources.- II. Absorption of Dietary Essential Fatty Acids.- III. Distribution of Absorbed Essential Fatty Acids Between Organs.- IV. The Requirement for Detergents for the Intestinal or Gastric Absorption of Essential Fatty Acids.- D. Gastric Mucosal Synthesis of Endogenous Prostanoids from Dietary Essential Fatty Acids.- I. The Requirement for Detergents for Absorption of Dietary Essential Fatty Acids into the Gastric Mucosa.- II. The Requirement for Direct Gastric Mucosal Contact with Solubilized Essential Fatty Acids for Mucosal Protection.- III. Generation of Prostanoids by the Gastric Mucosa from Solubilized Essential Fatty Acids.- E. Gastric Mucosal Protection by Solubilized Essential Fatty Acids.- I. Angiogenic Effect of Essential Fatty Acids.- F. Dietary Intake of Essential Fatty Acids.- I. Animal Studies.- II. Human Intake of Dietary Essential Fatty Acids and Its Relationship to Peptic Ulcer Disease.- G. Potential Therapeutic Advantages of Dietary Essential Fatty Acids Over the Synthetic Prostaglandins.- I. Effect of Short-Term Treatment with Dietary Essential Fatty Acids on the Human Gastric Mucosa.- H. Summary and Conclusion.- References.- 5 Helicobacter pylori.- A. Introduction.- B. Clinical Relevance of Helicobacter pylori.- I. Frequency in the General Population and Association with Chronic Gastritis and Peptic Ulcer Disease.- II. Causation.- 1. Chronic Gastritis.- 2. Peptic Ulcer Disease.- C. Attempts to Eradicate Helicobacter pylori.- I. Natural History.- II. Eradication of Helicobacter pylori Infections.- III. Methods to Confirm Eradication of Helicobacter pylori Infections.- IV. Bismuth Salts.- V. Antimicrobials as Monotherapy.- VI. Drug Combinations.- 1. Triple Drug Combinations.- 2. Double Drug Combinations.- VII. Toxicity of Antimicrobials and Bismuth Salts.- VIII. Experimental Therapeutic Approaches.- D. Eradication of Helicobacter pylori and Peptic Ulcer Disease.- I. Effect on Gastritis.- II. Effect on Healing of Duodenal Ulcers.- III. Effect on Relapse Rates of Duodenal Ulcers.- IV. Effect on Relapse Rates of Gastric Ulcers.- E. Whom to Treat and What to Expect?.- F. Summary and Conclusions.- References.- 6 Development of a New Gastric Antisecretory Drug for Clinical Use.- A. General Considerations.- B. Etiology and Pathophysiology of Peptic Ulcer.- C. Scope for Pharmacological Intervention.- D. Clinical Development of a New Antisecretory Drug for Peptic Ulcer.- I. Phase I.- II. Phase II.- III. Phase III.- IV. Phase IV.- References.- 7 Therapeutic use of Omeprazole in Man: Pharmacology, Efficacy, Toxicity, and Comparison with H2 Receptor Antagonists.- A. Introduction.- B. Pharmacology.- I. General.- II. Plasma Concentrations.- III. Inhibition of Acid Secretion.- IV. Other Actions of Omeprazole.- 1. Effect on Secretion of Intrinsic Factor and Vitamin B12 Absorption.- 2. Effect on Pepsin.- 3. Effects on Motility.- 4. Effects on Gastric Endocrine function.- C. Therapeutic Trials in Acid-Peptic Diseases.- I. Overview.- II. DuodenalUlcer.- 1. Effect of Different Doses of Omeprazole.- 2. Comparative Studies of Omeprazole and H2 Receptor Antagonists.- 3. Relapse After Stopping Omeprazole Therapy.- 4. Omeprazole Treatment for Ulcers Resistant to H2 Receptor Antagonists.- III. Gastric Ulcer.- 1. Noncomparative Studies of Omeprazole.- 2. Comparative Studies of Omeprazole and Ranitidine.- 3. Relapse After Stopping Omeprazole Therapy.- 4. Omeprazole Treatment for Ulcers Resistant to H2 Receptor Antagonists.- IV. Reflux Esophagitis.- 1. Effect of Different Doses of Omeprazole.- 2. Comparative Studies of Omeprazole and H2 Receptor Antagonists.- 3. Relapse After Stopping Omeprazole Therapy.- 4. Omeprazole Treatment for Reflux Esophagitis Resistant to H2 Receptor Antagonists.- V. Zollinger-Ellison Syndrome.- VI. Side-Effects and Toxicity.- D. Probable Role of Omeprazole in Acid-Peptic Diseases.- References.- 8 Hypothesis of Peptic Ulcer: A Modern Classification of a Multifactorial Disease.- A. Introduction.- B. Histopathology of Peptic Ulcer.- I. Ulcer Histology.- II. Gastritis - Definitions.- 1. Endoscopic Gastritis.- 2. Histologic Gastritis.- C. Schwarz's Balance.- I. Mucosal Defenses.- 1. Measurement of the Barrier.- 2. The Mucus Gel and pH Gradient.- 3. Mucosal Healing.- 4. Mucosal Bloodflow.- 5. Other Mechanisms of Defense.- II. Aggressive Factors.- 1. Hydrogen Ion.- 2. Aspartic Proteinases.- 3. Bile Acids.- 4. Oxygen Free Radicals.- III. Risk Factors as Modifiers of Mucosal Defense.- 1. Blood Groups.- 2. Tobacco Use.- IV. Regulation of Mucosal Defenses: Prostaglandins and Epidermal Growth Factor.- 1. Role of Prostaglandins in Mucosal Defense.- 2. Epidermal Growth Factor and Other Factors.- D. Classification of Peptic Ulcer Disease.- E. Drug-Induced Ulcer Disease.- I. Nonsteroidal Anti-Inflammatory Drugs and Aspirin.- 1. Mechanisms of NSAID-Induced Injury.- 2. Lesions Associated with NSAID Ingestion.- 3. Helicobacter pylori and NSAID Ingestion.- II Drug-Induced Ulcers - Alcohol.- 1. Mechanisms of Injury.- 2. Ethanol ad Ulcers.- III. Drug-Induced Ulcers - Steroids.- 1. Corticosteroids and Ulcers.- 2. Effects of Corticosteroids on the Mucosa.- F. Helicobacter pylori and Peptic Ulcer.- 1. Helicobacter pylori.- 2. The Effect of Helicobacter pylori on the Mucosa and the Host Response.- 3. Helicobacter pylori- Associated Gastroduodenal Ulcers.- G. Ulcers Associated with Hypersecretory States.- H. Malignant Ulcers.- J. Other Types of Chronic Relapsing Peptic Ulcer.- K. Acute Mucosal Stress Ulceration.- L. Summary.- References.- 9 Nonulcer Dyspepsia.- A. Introduction.- B. Definition.- C. Epidemiology.- D. Categories of Nonulcer Dyspepsia.- I. Gastroesophageal Reflux-Like Dyspepsia.- II. Dysmotility-Like Dyspepsia.- III. Ulcer-Like Dyspepsia.- IV. Aerophagia.- V. Idiopathic/Essential Dyspepsia.- E. Pathophysiology.- I. Gastric Acid.- II. Helicobacter pylori.- III. Motility.- IV. Psychosocial Factors.- V. Environmental Factors.- F. Diagnostic Approach.- G. Treatment.- H. Prognosis.- J. Conclusions.- References.- 10 The Natural History of Duodenal Ulcer Disease: Has it been Altered by Drug Therapy?.- A. Introduction.- B. Incidence of Duodenal Ulcer - Historical Perspectives.- I. Cohort Phenomena.- C. Recent Time Trends in the Incidence of Duodenal Ulcer.- D. Geographic Influences.- E. Recent Trends in Hospitalization and Surgery for Duodenal Ulcer.- F. Seasonal Variations in Duodenal Ulcer.- I. Seasonal Variations Studied Endoscopically.- G. Natural History of Duodenal Ulcer - Pre-H2 Blocker Studies.- I. Scandinavian Studies.- II. European Studies.- III. CURE Study.- H. Duodenal Ulcer Disease in the H2 Blocker Era.- I. How Long Does a Duodenal Ulcer Stay Healed After Treatment?.- J. Role of Helicobacter pylori.- K Natural History of Untreated Ulcers.- L. Natural History of Unhealed Ulcers.- M. Can Drug Therapy Prevent Duodenal Ulcer Relapse?.- N. Other Agents for "Short-Term" Maintenance Therapy.- I. Antacids.- II. Anticholinergics.- III. Tricyclic Antidepressants.- IV. Sucralfate.- V. Bismuth.- VI. Omeprazole.- O. How Long Should Maintenance Therapy Be Continued?.- I. On-Demand Versus Intermittent Therapy.- P. Summary.- References.- 11 Refractory Duodenal Ulcer.- A. Introduction.- I. Definition.- II. Adequate Treatment and Compliance.- III. Hypersecretory Disorders and Nonpeptic Ulcer Disease.- B. Factors Which Affect Healing and Recurrence.- I. Acid Hypersecretion.- 1. Parietal Cell Sensitivity.- 2. Tolerance.- 3. Rebound Hypersecretion.- 4. Gastrin.- 5. Clinical Significance.- II. Smoking.- III. Nonsteroidal Anti-Inflammatory Drugs.- IV. Helicobacter pylori.- V. Ulcer Morphology.- C. Outcome of Refractory Duodenal Ulcer Treatment Trials.- I. Acid Suppression.- II. Mucosal Protective Agents.- III. Surgery.- D. Management.- I. General Advice.- II. Specific Treatment.- References.- 12 Idiopathic Gastric Acid Hypersecretion.- A. Introduction.- B. Method of Doing Gastric Analysis.- C. Definition of Idiopathic Gastric Acid Hypersecretion.- I. Statistical Definition.- II. Functional Definition.- D. Diseases Associated with Idiopathic Gastric Acid Hypersecretion.- I. Gastroesophageal Reflux Disease.- II. Duodenal Ulcer Disease.- III. Gastric Ulcer Disease.- IV. Nonulcer Dyspepsia.- E. Comparison of Idiopathic Gastric Acid Hypersecretion and Zollinger-Ellison Syndrome.- I. Characteristics.- II. Basal Acid Output, Maximal Acid Output, and Basal Acid Output/Maximal Acid Output Ratio.- F. Helicobacter pylori Associated with Idiopathic Gastric Acid Hypersecretion.- G. Therapy for Idiopathic Gastric Acid Hypersecretion.- H. Other Data on Idiopathic Gastric Acid Hypersecretion.- I. Basal Acid Output in Children.- II. Basal Acid Output in Other Disorders.- J. Conclusions.- References.- 13 Zollinger-Ellison Syndrome: Advances in Diagnosis and Management.- A. Introduction.- B. Pathophysiology.- C. Clinical Features.- D. Provocative Tests.- E. Differential Diagnosis of Disorders with Increased Basal Acid Output and Increased Fasting Gastrin Concentration.- F. Medical Therapy.- I. H2 Receptor Antagonists.- 1. General.- 2. Absorption and Excretion of H2 Receptor Antagonists.- 3. Studies in Patients with Zollinger-Ellison Syndrome.- 4. Potency.- 5. Onset of Action.- 6. Duration of Action.- 7. Failure.- 8. Safety.- 9. Use.- 10. Use of Parenteral H2 Receptor Antagonists.- II. Omeprazole.- 1. General.- 2. Absorption, Metabolism, and Excretion.- 3. Onset of Action.- 4. Duration of Action.- 5. Potency.- 6. Failure..- 7. Use.- 8. Safety.- III. Anticholinergic Agents.- IV. Prostaglandins.- V. Somatostatin or SMS 201-995.- VI. Gastrin Receptor Antagonists.- G. Surgical Therapy.- H. Tumor Localization.- J. Treatment of Metastatic Disease.- References.- 14 The Pathophysiology and Treatment of Gastroesophageal Reflux Disease.- A. Introduction.- B. The Nosology of Reflux.- C. Why Do Humans Reflux?.- D. Variability of Tissue Response to Reflux.- E. Sequelae of Gastroesophageal Reflux.- F. Extraesophageal Manifestations of Reflux.- G. Testing in Gastroesophageal Reflux.- H. Treatment of Gastroesophageal Reflux.- J. Surgery in Gastroesophageal Reflux.- K Management in Real Life.- L. Summary.- References.- 15 Endoscopy in the Evaluation and Treatment of Acid-Peptic Disease.- A. Introduction.- B. Accuracy.- C. Safety.- D. Uncomplicated Acid-Peptic Disease.- I. Endoscopy as the Initial Diagnostic Modality.- II. Endoscopy Following a Radiologic Procedure.- 1. Negative Upper Gastrointestinal Series.- 2. Gastric Ulcer.- 3. Duodenal Ulcer.- III. Biopsy and Cytology.- IV. Disease Follow-up.- E. Gastrointestinal Bleeding from Acid-Peptic Disease.- I. Guidelines for Intervention.- II. Stigmata of Bleeding.- III. Endoscopic Hemostasis.- 1. Electrocoagulation.- 2. Photocoagulation.- 3. Heater Probe.- 4. Chemical Injection.- 5. Comparison of Hemostatic Modalities.- F. Gastric Outlet Obstruction.- G. Summary.- References.- 16 Videoendoscopy and Digital Imaging.- A. Introduction.- B. Charge-Coupled Devices and Videoendoscopy - How They Work..- I. Background.- II. CCD function.- III. Image Transfer.- IV. Microprocessor function.- V. Color.- 1. Background.- 2. Videoendoscopic Color Reproduction.- VI. Technical Evaluation.- VII. Clinical Use.- C. Practical Benefits and Advantages of Videoendoscopy.- I. Image Storage, Retrieval, and Transfer.- II. Teaching/Other.- D. Special Applications.- I. Measurement of Lesion Size.- II. Real-Time Image Analysis.- III. Image Modification.- IV. Chromoscopy and Infrared Imaging.- V. Mucosal Hemodynamics.- VI. Videoenteroscopy.- E. The Future.- References.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag Berlin and Heidelberg GmbH & Co. K)
Publication date: December, 2011
Pages: 492
Weight: 739g
Availability: Available
Subcategories: Pharmacology
From the same series
Roger G. Pertwee
Philip K. Moore
Kathleen M. Kantak
Alan Cowan
Hans-Georg Schaible
Arnold von Eckardstein
Mark A. Geyer
Botond Berde
Lorenzo A. Pinna
Arnold von Eckardstein
Mark A. Geyer
Anthony R.M. Coates
Vera Regitz-Zagrosek
Ursula F. Habenicht
Christoph Stein
Fabrizio Benedetti
Paolo Gresele
O. Eichler
Clive P. Page
Peter Ruben
G. Peters
Gary R. Lewin
Allison D. Fryer
Hans-Georg Joost
Vsevolod V. Gurevich
Hannsjorg W. Seyberth
Sharron H. Francis
George B. Koelle
Marc Humbert
G Kimmerle
Martha Merrow
Erich Gulbins
Martin C. Michel
Mathias Schwanstecher
Erich Gulbins
Martin F. Fromm
Ross G. Cameron
Hanns Mohler
Mark A. Geyer
F. Clementi
Peter Holzer
Gaetano Di Chiara
Anthony R. M. Coates
David S. Latchman
Siamon Gordon
Bernard Testa
Michael Oettel
B. Mayer
Klaus, von der Helm
Sheldon H. Preskorn
Lutz Hein
Heinz Nau
Stanley T. Crooke
J.M. Monti
Martin C. Michel
Vera Regitz-Zagrosek
Mark A. Geyer
G. Peters
Paolo Gresele
Manfred Gossen
Maynard B. Chenoweth
W. McD. Armstrong
Clive P. Page
Monika Schafer-Korting
Detlef Thieme
Fiona Cunningham
Vittorio Erspamer
Hans H. Ussing
Oskar Eichler
Ervin G. Erdös
S. Bettini
R.E.M. Bowden
John Morley
P.S. Randall
H. Winkler
R Jahn
J. Harenberg
F. Bachmann
D.J. Atherton
M.T. Jones
Frank A. Smith
Timothy D. Warner
Jochen Kuhlmann
James R. Gillette
Joel Bockaert
M. Chatterjee
A.P. Weetman
M. Sovak
Clive P. Page
James William Fisher
Hans-Georg Joost
D.I. Abramson
H.P. Witschi
R. Assan
Alfred J. Clark
J.M. van Rossum
Helmut Greim
Allison D. Fryer
Michael Oettel
M.L. Sears
R. Hess
P.E. Came
C.F. Arlett
H. Mehnert
W.N. Kelley
Luc P. Balant
Alan C. Sartorelli
Gregory R. Mundy
W. R. Martin
Peter Perlman
Michael B. Sporn
Harold C. Hodge
David R. Brown
C. Muller
J. Erik Jorpes
H.E. Voss
Peter Frederick Baker
Pedro Cuatrecasas
Laszlo Szekeres
Fritz Markwardt
R. Baserga
D.A. Kharkevich
H. Vanden Bossche
Ronald T. Borchardt
Alain L. de Weck
Lawrence E. Bryan
T.J. Campbell
F. Lang
K. Bartmann
Donald B. Calne
E.M. Johnson
G.H. Hitchings
Arnold L. Demain
Eugen Dorzbach
U. Peters
M. Green
A. S. Milton
R. Baurain
Brian W. Fox
W. Bleifeld
P. Actor
H. Vanden Bossche
Victor P. Whittaker
Ullrich Trendelenburg
D. Janz
Börje Uvnäs
H.G. Baumgarten
J. A. Nathanson
Frederick C. Kauffman
S. Silver
Kurt Greeff
B. Babudieri
J.G. Banwell
T.T. Aoki
A.L. Jr. Ager
M. Ackenheil
M. Rocha e Silva
Carlo Patrono
Hamao Umezawa
W. Rogalski
G. R. Strichartz
E.C. Foulkes
P. Needleman
E. Anggard
H. Schmidt
C. Braestrup
L.G. Abood
D.A. Kharkevich
C.-Y. Lee
Charles D. Kochakian
Robert Charlier
A.C. Allison
I.H. Page
James R. Gillette
Hermann Blaschko
K.W. Bock
Dean H. Lockwood
A. Dickenson
Franz von Bruchhausen
P.F. D'Arcy
Robert J. Kavlock
Andrew C.G. Uprichard
P.J. Lefebvre
Mervyn J. Eadie
Franz Hefti
Ross G. Cameron
John G. Csernansky
Michael J. Kuhar
Hannsjorg W. Seyberth
Sharron H. Francis
Mathias Schwanstecher
Martin C. Michel
Martin R. Wilkins
Martin F. Fromm
Peter Redfern
Klaus Aktories
Jurgen Behrens
Harri U. Vainio
Michael Williams
Dennis W. Choi
Gaetano Di Chiara
Peter Jonas
Salvador Moncada
Stefan Bauer
Markus Schwaiger
Markus Schwaiger
Jurgen Schuttler
Hans-Georg Krausslich
Veit M. Flockerzi
Harald H.H.W. Schmidt
Thomas C. Sudhof
Eric Beitz
Kian Fan Chung
Andreas Michael Zeiher
Yuti Chernajovsky
Jack E. Henningfield
Giovanna Lombardi
Salvador Moncada
Florian Holsboer
Enno Klussmann
Clive P. Page
Bertil B. Fredholm
Ursula F. Habenicht
Fiona Cunningham
Monika Schafer-Korting
Matthias Gaestel
Volker A. Erdmann
Robert E. Kass
Harald Sitte
Detlef Thieme
Domenico Spina
Constance N. Wilson
Jack E. Henningfield
Eric Beitz
Harald H.H.W. Schmidt
Giovanna Lombardi
Hans-Georg Krausslich
Kian Fan Chung
Markus Schwaiger
Markus Schwaiger
Enno Klussmann
Anna M. Wobus
Jurgen Schuttler
Thomas C. Sudhof
Stefan Bauer
Yuti Chernajovsky
Andreas Michael Zeiher
Veit M. Flockerzi
Christoph Stein
Salvador Moncada
Salvador Moncada
Harald Sitte